Autopsy report · NCT05135546

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

“No patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 5 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Supergene, LLC

Sponsor type

Industry

Conditions

COVID-19

Interventions

Recombinant nonimmunogenic staphylokinase; Placebo

Participants

4

Sites

2

Countries

Russia

Trials that died the same way

• Hepatic Mitochondrial Function in Sepsis
  “no patients to include” (87% match in meaning)
• Exploration of the Enteric Nervous System in Alzheimer Disease
  “no patients included” (87% match in meaning)
• Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients
  “No patients recruited” (82% match in meaning)
• Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis
  “no patients were included” (82% match in meaning)
• QLESP Block in Hip Surgery
  “No patients enrolled” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.